BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
the University of Alberta has received thirty-eight additional patents for the
Company's synthetic peptide therapeutic, MBP8298, for the treatment of
multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these
patents on an exclusive worldwide basis from the University of Alberta.
